The Relevance of Clinical Trials and Real-World Data

At EADV 2026 | Date: Saturday, October 3, 2026 | Time: 2:15 - 5:30 PM CEST

Austria Center Vienna, Bruno-Kreisky-Platz 1, 1220, Vienna, Austria

REGISTER NOW

PROGRAM CHAIRS

PROGRAM DESCRIPTION 

This session will examine how clinical trials and real-world evidence are shaping current and future care in atopic dermatitis. Faculty will review practical lessons from trial setup and late-phase study design, address challenges in pediatric research, and discuss how emerging data on biomarkers, disease heterogeneity, treatment patterns, safety, and regulatory-grade evidence can help bridge mechanistic insights with clinical decision-making.

LEARNING OBJECTIVES

At the end of the session, participants will be able to:

1. Describe key operational and design considerations involved in setting up and conducting late-phase clinical trials in atopic dermatitis.
2. Compare the strengths and limitations of clinical trial data and real-world evidence when evaluating treatment effectiveness and safety, including in pediatric populations.
3. Identify how biomarkers, phenotype-endotype correlations, and high-quality registry or real-world datasets may support patient stratification and treatment decision-making in atopic dermatitis.

AGENDA

2:15-2:25 PM Welcome from the IEC
Alan Irvine, MD DSc | IEC President | Trinity College Dublin, Children’s Health | Dublin, Ireland

2:25-2:30 PM Program overview
Thomas Bieber, MD PhD MDRA | IEC Councilor | Professor of Dermatology and Allergy, Ludwig-Maximilians University | Munich, Germany.
Kenji Kabashima, MD PhD | IEC Secretary | Professor, Department of Dermatology | Kyoto University Graduate School of Medicine | Kyoto, Japan

Part 1: Clinical Trials: What Have We Learned?

2:30-2:45 PM From Protocol to Patient: Mastering the Logistics of Clinical Trial Setup
Robert Bissonnette, MD FRCPC MSc | IEC Past President | Chairman, Indero (formerly Innovaderm) | Montreal, QC, Canada

2:45-3 PM Designing Late-Phase Trials
Andy Blauvelt, MD MBA | IEC Councilor | Blauvelt Consulting, LLC

3-3:15 PM Children First? The Complex Reality of Pediatric Trials in Atopic Dermatitis
Alan Irvine, MD DSc | IEC President | Professor of Dermatology | Trinity College Dublin, Children’s Health | Dublin, Ireland

Part 2: Real-World Data: Effectiveness, Safety, and Treatment Patterns

3:15-3:30 PM From Cytokine Circuits to Clinical Outcomes: How Clinical Trials Have Redefined Atopic Dermatitis
Kenji Kabashima, MD PhD | IEC Secretary | Professor, Department of Dermatology | Kyoto University Graduate School of Medicine | Kyoto, Japan

3:30-3:45 PM Q & A | All Previous Speakers, Parts 1-2

3:45-4 PM BREAK

Part 3: Bridging Trials and Real-World Evidence

4-4:25 PM Drawback of clinical decision making based on clinical trial data and challenges of RWE
Marjolein De Bruin-Weller, MD PhD | IEC Councilor | University Medical Center | Utrecht, Netherlands

4:25-4:50 PM Phenotype-endotype correlation: Translational Aspects Bridging Mechanistic Insights and Clinical Stratification
Kilian Eyerich, MD PhD | IEC Councilor | Freiburg, Germany

4:50-5:10 PM The long and challenging way to “regulatory grade” data in registries and real-world evidence
Thomas Bieber, MD PhD MDRA | IEC Councilor | Professor of Dermatology and Allergy, Ludwig-Maximilians University, Munich, Germany

5:10-5:25 PM Q & A | All Previous Speakers, Part 3

5:25-5:30 PM Program summary & concluding remarks
Thomas Bieber, MD PhD MDRA | IEC Councilor | Professor of Dermatology and Allergy, Ludwig-Maximilians University, Munich, Germany.
Kenji Kabashima, MD PhD | IEC Secretary | Professor, Department of Dermatology | Kyoto University Graduate School of Medicine | Kyoto, Japan

Please check back with us for updates.

This educational symposium presented by the IEC is offered at no cost to attendees.